347 related articles for article (PubMed ID: 18544001)
21. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.
Purkins L; Wood N; Kleinermans D; Greenhalgh K; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):17-23. PubMed ID: 14616409
[TBL] [Abstract][Full Text] [Related]
22. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
23. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
24. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis).
Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN
Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055
[TBL] [Abstract][Full Text] [Related]
26. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
27. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.
Purkins L; Wood N; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):51-5. PubMed ID: 14616414
[TBL] [Abstract][Full Text] [Related]
28. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
[TBL] [Abstract][Full Text] [Related]
30. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
[TBL] [Abstract][Full Text] [Related]
31. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function.
Alvarez-Lerma F; Allepuz-Palau A; Garcia MP; Angeles Leon M; Navarro A; Sanchez-Ruiz H; Iruretagoyena JR; Luque-Gomez P;
J Chemother; 2008 Feb; 20(1):93-100. PubMed ID: 18343750
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.
Peng LW; Lien YH
Am J Kidney Dis; 2005 Jan; 45(1):162-6. PubMed ID: 15696456
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N
Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217
[TBL] [Abstract][Full Text] [Related]
34. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
Liu P; Foster G; Gandelman K; LaBadie RR; Allison MJ; Gutierrez MJ; Sharma A
Antimicrob Agents Chemother; 2007 Oct; 51(10):3617-26. PubMed ID: 17646413
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
36. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell JA; Schranz J; Baruch A; Foster G
J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
[TBL] [Abstract][Full Text] [Related]
37. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).
Flammer K; Nettifee Osborne JA; Webb DJ; Foster LE; Dillard SL; Davis JL
Am J Vet Res; 2008 Jan; 69(1):114-21. PubMed ID: 18167096
[TBL] [Abstract][Full Text] [Related]
40. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
